BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Binder L, Schwörer H, Hoppe S, Streit F, Neumann S, Beckmann A, Wachter R, Oellerich M, Walson PD. Pharmacokinetics of meropenem in critically ill patients with severe infections. Ther Drug Monit. 2013;35:63-70. [PMID: 23318279 DOI: 10.1097/ftd.0b013e31827d496c] [Cited by in Crossref: 31] [Cited by in F6Publishing: 13] [Article Influence: 3.4] [Reference Citation Analysis]
Number Citing Articles
1 Einav S, O'Connor M, Chavez LO. Visit to intensive care of 2050. Intensive Care Med 2017;43:97-100. [PMID: 27581682 DOI: 10.1007/s00134-016-4525-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
2 Del Bono V, Giacobbe DR, Marchese A, Parisini A, Fucile C, Coppo E, Marini V, Arena A, Molin A, Martelli A, Gratarola A, Viscoli C, Pelosi P, Mattioli F. Meropenem for treating KPC-producing Klebsiella pneumoniae bloodstream infections: Should we get to the PK/PD root of the paradox? Virulence 2017;8:66-73. [PMID: 27430122 DOI: 10.1080/21505594.2016.1213476] [Cited by in Crossref: 37] [Cited by in F6Publishing: 36] [Article Influence: 6.2] [Reference Citation Analysis]
3 Goncalves-Pereira J, Silva NE, Mateus A, Pinho C, Povoa P. Assessment of pharmacokinetic changes of meropenem during therapy in septic critically ill patients. BMC Pharmacol Toxicol 2014;15:21. [PMID: 24731745 DOI: 10.1186/2050-6511-15-21] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 3.5] [Reference Citation Analysis]
4 Trubiano JA, Worth LJ, Thursky KA, Slavin MA. The prevention and management of infections due to multidrug resistant organisms in haematology patients. Br J Clin Pharmacol 2015;79:195-207. [PMID: 24341410 DOI: 10.1111/bcp.12310] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 4.6] [Reference Citation Analysis]
5 Busse D, Simon P, Schmitt L, Petroff D, Dorn C, Dietrich A, Zeitlinger M, Huisinga W, Michelet R, Wrigge H, Kloft C. Comparative Plasma and Interstitial Tissue Fluid Pharmacokinetics of Meropenem Demonstrate the Need for Increasing Dose and Infusion Duration in Obese and Non-obese Patients. Clin Pharmacokinet 2021. [PMID: 34894344 DOI: 10.1007/s40262-021-01070-6] [Reference Citation Analysis]
6 Mahmoud SH, Shen C. Augmented Renal Clearance in Critical Illness: An Important Consideration in Drug Dosing. Pharmaceutics 2017;9:E36. [PMID: 28926966 DOI: 10.3390/pharmaceutics9030036] [Cited by in Crossref: 44] [Cited by in F6Publishing: 32] [Article Influence: 8.8] [Reference Citation Analysis]
7 Xiao AJ, Miller BW, Huntington JA, Nicolau DP. Ceftolozane/tazobactam pharmacokinetic/pharmacodynamic-derived dose justification for phase 3 studies in patients with nosocomial pneumonia. J Clin Pharmacol 2016;56:56-66. [PMID: 26096377 DOI: 10.1002/jcph.566] [Cited by in Crossref: 101] [Cited by in F6Publishing: 94] [Article Influence: 14.4] [Reference Citation Analysis]
8 Braune S, König C, Roberts JA, Nierhaus A, Steinmetz O, Baehr M, Kluge S, Langebrake C. Pharmacokinetics of meropenem in septic patients on sustained low-efficiency dialysis: a population pharmacokinetic study. Crit Care 2018;22:25. [PMID: 29382394 DOI: 10.1186/s13054-018-1940-1] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
9 Thémans P, Marquet P, Winkin JJ, Musuamba FT. Towards a Generic Tool for Prediction of Meropenem Systemic and Infection-Site Exposure: A Physiologically Based Pharmacokinetic Model for Adult Patients with Pneumonia. Drugs R D 2019;19:177-89. [PMID: 31090024 DOI: 10.1007/s40268-019-0268-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
10 D'Cunha R, Bach T, Young BA, Li P, Nalbant D, Zhang J, Winokur P, An G. Quantification of Cefepime, Meropenem, Piperacillin, and Tazobactam in Human Plasma Using a Sensitive and Robust Liquid Chromatography-Tandem Mass Spectrometry Method, Part 1: Assay Development and Validation. Antimicrob Agents Chemother 2018;62:e00859-18. [PMID: 29941654 DOI: 10.1128/AAC.00859-18] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
11 Lonsdale DO, Baker EH, Kipper K, Barker C, Philips B, Rhodes A, Sharland M, Standing JF. Scaling beta-lactam antimicrobial pharmacokinetics from early life to old age. Br J Clin Pharmacol 2019;85:316-46. [PMID: 30176176 DOI: 10.1111/bcp.13756] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
12 Mattioli F, Fucile C, Del Bono V, Marini V, Parisini A, Molin A, Zuccoli ML, Milano G, Danesi R, Marchese A, Polillo M, Viscoli C, Pelosi P, Martelli A, Di Paolo A. Population pharmacokinetics and probability of target attainment of meropenem in critically ill patients. Eur J Clin Pharmacol 2016;72:839-48. [PMID: 27048201 DOI: 10.1007/s00228-016-2053-x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 5.2] [Reference Citation Analysis]
13 Keller F, Schröppel B, Ludwig U. Pharmacokinetic and pharmacodynamic considerations of antimicrobial drug therapy in cancer patients with kidney dysfunction. World J Nephrol 2015; 4(3): 330-344 [PMID: 26167456 DOI: 10.5527/wjn.v4.i3.330] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
14 Cojutti P, Sartor A, Righi E, Scarparo C, Bassetti M, Pea F. Population Pharmacokinetics of High-Dose Continuous-Infusion Meropenem and Considerations for Use in the Treatment of Infections Due to KPC-Producing Klebsiella pneumoniae. Antimicrob Agents Chemother 2017;61:e00794-17. [PMID: 28760900 DOI: 10.1128/AAC.00794-17] [Cited by in Crossref: 22] [Cited by in F6Publishing: 9] [Article Influence: 4.4] [Reference Citation Analysis]